Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERAD-IMMUNE: Nivolumab and Ipilimumab in Cervical Cancer
NCT05504642Phase 2Withdrawn
- Sponsor
- University Hospital Cologne
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Cervical Cancer (CC), sponsored by University Hospital Cologne. Planned start Nov 2023; status: withdrawn.
02
Drugs
nivolumabipilimumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05504642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504642.